CY1118835T1 - Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει - Google Patents

Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει

Info

Publication number
CY1118835T1
CY1118835T1 CY20171100446T CY171100446T CY1118835T1 CY 1118835 T1 CY1118835 T1 CY 1118835T1 CY 20171100446 T CY20171100446 T CY 20171100446T CY 171100446 T CY171100446 T CY 171100446T CY 1118835 T1 CY1118835 T1 CY 1118835T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
antibody
fgf23
composition including
fgf23 antibody
Prior art date
Application number
CY20171100446T
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of CY1118835T1 publication Critical patent/CY1118835T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Για παροχή ενός αντισώματος έναντι FGF23 και μιας φαρμακευτικής σύνθεσης ως ενός προληπτικού ή θεραπευτικού παράγοντα ο οποίος να μπορεί να ασκήσει προληπτική ή θεραπευτική δράση μέσω καταστολής μιας δράσης του FGF23 μέσω χρήσης του αντισώματος. Ένα αντίσωμα ή το λειτουργικό του θραύσμα έναντι ανθρώπινου FGF23 που παράγεται από υβρίδωμα C10 (Αριθμός Εισαγωγής FERM BP-10772).
CY20171100446T 2007-02-14 2017-04-19 Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει CY1118835T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
EP08711707.3A EP2128253B1 (en) 2007-02-14 2008-02-14 Anti-fgf23 antibody and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
CY1118835T1 true CY1118835T1 (el) 2018-01-10

Family

ID=39690189

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100446T CY1118835T1 (el) 2007-02-14 2017-04-19 Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
CY2018021C CY2018021I2 (el) 2007-02-14 2018-08-07 Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
CY20201100713T CY1123240T1 (el) 2007-02-14 2020-08-03 Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2018021C CY2018021I2 (el) 2007-02-14 2018-08-07 Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
CY20201100713T CY1123240T1 (el) 2007-02-14 2020-08-03 Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει

Country Status (23)

Country Link
US (4) US7883705B2 (el)
EP (3) EP2502996B1 (el)
JP (1) JP4800396B2 (el)
KR (1) KR101462291B1 (el)
CN (2) CN102702355B (el)
AU (1) AU2008215346B2 (el)
CA (1) CA2677782C (el)
CY (3) CY1118835T1 (el)
DK (3) DK3181691T3 (el)
ES (3) ES2811318T3 (el)
FR (1) FR18C1032I2 (el)
HK (2) HK1140228A1 (el)
HR (2) HRP20170548T1 (el)
HU (3) HUE050517T2 (el)
LT (3) LT2502996T (el)
LU (2) LUC00082I2 (el)
NL (1) NL300945I2 (el)
NO (1) NO2018025I1 (el)
PL (3) PL2128253T3 (el)
PT (3) PT3181691T (el)
SI (2) SI2502996T1 (el)
TW (1) TWI422593B (el)
WO (1) WO2008099969A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4799801B2 (ja) * 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
EP1466925B1 (en) * 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
ES2851674T3 (es) 2014-06-09 2021-09-08 Ultragenyx Pharmaceutical Inc Control efectivo y eficaz de fosfato sérico para una formación ósea óptima
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
WO2018181935A1 (ja) 2017-03-30 2018-10-04 シスメックス株式会社 抗ＡｐｏＡ１抗体
US20220185876A1 (en) * 2019-03-29 2022-06-16 Atarga, Llc Anti fgf23 antibody
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (el) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US20020102604A1 (en) 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
ES2281964T3 (es) 1998-05-18 2007-10-01 University College London Hormona polipeptidica derivada de tumor humano fosfatonina.
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
AU3924300A (en) 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666494A1 (en) 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1246843A1 (en) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
AU2001239765A1 (en) 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001061007A2 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
WO2001066596A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
CN1446227B (zh) 2000-07-19 2011-10-05 先端研究与技术学院 新型成纤维细胞生长因子(fgf23)及其使用方法
JP4799801B2 (ja) 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
US20040171825A1 (en) 2001-04-26 2004-09-02 Lydie Bougueleret Human fibroblast growth factor-related compositions
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
EP1466925B1 (en) 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
WO2004083425A1 (ja) * 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
EP1753783B1 (en) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
ZA200701656B (en) * 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
CA2579391C (en) * 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
WO2006078072A1 (ja) 2005-01-21 2006-07-27 Kirin Beer Kabushiki Kaisha キメラ非ヒト動物およびその使用
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU2008215346B2 (en) 2013-01-10
LTPA2018508I1 (lt) 2018-09-10
FR18C1032I2 (fr) 2019-08-09
ES2811318T3 (es) 2021-03-11
EP2128253B1 (en) 2014-12-03
ES2530670T3 (es) 2015-03-04
DK2128253T3 (en) 2015-01-05
EP2128253A1 (en) 2009-12-02
SI2502996T1 (sl) 2017-08-31
EP3181691A1 (en) 2017-06-21
PL2502996T3 (pl) 2017-07-31
NL300945I2 (en) 2020-05-13
NO2018025I1 (no) 2018-08-09
DK3181691T3 (da) 2020-08-17
SI3181691T1 (sl) 2020-09-30
PT2502996T (pt) 2017-05-10
EP3181691B1 (en) 2020-07-15
US10202446B2 (en) 2019-02-12
HK1172917A1 (en) 2013-05-03
EP2502996B1 (en) 2017-03-29
PL3181691T3 (pl) 2020-11-02
NL300945I1 (en) 2018-08-15
JP4800396B2 (ja) 2011-10-26
TWI422593B (zh) 2014-01-11
KR20090114452A (ko) 2009-11-03
LUC00081I2 (el) 2018-10-01
US20090148461A1 (en) 2009-06-11
FR18C1032I1 (el) 2018-08-31
HRP20170548T1 (hr) 2017-08-25
PT2128253E (pt) 2015-02-04
HUE031728T2 (en) 2017-07-28
US20110182913A1 (en) 2011-07-28
CA2677782C (en) 2016-07-26
PL2128253T3 (pl) 2015-04-30
LT2502996T (lt) 2017-06-26
HUE050517T2 (hu) 2020-12-28
CY2018021I1 (el) 2019-07-10
AU2008215346A1 (en) 2008-08-21
EP2128253A4 (en) 2010-03-10
US20190106485A1 (en) 2019-04-11
HUS1800034I1 (hu) 2018-09-28
EP2502996A2 (en) 2012-09-26
CA2677782A1 (en) 2008-08-21
US7883705B2 (en) 2011-02-08
JPWO2008099969A1 (ja) 2010-05-27
KR101462291B1 (ko) 2014-11-14
DK2502996T3 (en) 2017-05-08
TW200902549A (en) 2009-01-16
US9290569B2 (en) 2016-03-22
US20160159895A1 (en) 2016-06-09
WO2008099969A1 (ja) 2008-08-21
CN101652476A (zh) 2010-02-17
CN102702355A (zh) 2012-10-03
CN102702355B (zh) 2014-09-24
LUC00082I2 (el) 2018-10-01
HRP20201266T1 (hr) 2021-02-05
EP2502996A3 (en) 2013-04-10
LTC2502996I2 (lt) 2019-05-10
LT3181691T (lt) 2020-08-25
HK1140228A1 (en) 2010-10-08
CN101652476B (zh) 2012-07-04
CY1123240T1 (el) 2021-10-29
CY2018021I2 (el) 2019-07-10
ES2625823T3 (es) 2017-07-20
PT3181691T (pt) 2020-08-26

Similar Documents

Publication Publication Date Title
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
CY1112497T1 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CY1112724T1 (el) Παραγωγα ανθρακικης κουινουκλιδινης και ιατρικη συνθεση αυτων
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo